Boehringer Expands NASH R&D Pipeline With New Compound from Yuhan

• Boehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease – steatosis, inflammation and fibrosis
• Collaboration aims to develop first-in-class dual agonist (GLP1R/FGF21R agonist) for NASH
• Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties

 Boehringer Ingelheim Pharmaceuticals, Inc. and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one molecule. The collaboration brings together Yuhan Corporation’s expertise in FGF21 biology, obesity and NASH with Boehringer Ingelheim’s pharmaceutical expertise and commitment to bringing innovative medicines to patients with cardiometabolic diseases.

https://www.biospace.com/article/releases/boehringer-ingelheim-expands-nonalcoholic-steatohepatitis-nash-r-and-amp-d-pipeline-with-new-first-in-class-compound-from-yuhan-corporation/